Increasing prevalence of common diseases and conditions such as obesity, diabetes, hypertension, etc.,
are leading to the risk of various heart problems. Moreover, the rise in people suffering from high blood
pressure, and valvular heart disease due to the rheumatic fever are some of the most common risk
factors for atrial fibrillation.
Read Report Overview - https://www.transparencymarketresearch.com/atrial-fibrillation-market.html
Along with the increasing number of people suffering from atrial fibrillation, especially among the
geriatric population. There has been an advancement in diagnoses and treatment of atrial fibrillation.
Researchers and experts are also working together to find out new technologies to improve early
detection and diagnosis of atrial fibrillation and achieve maximum benefit for atrial fibrillation patients.
However, lack of well-trained physicians and the high cost of treatments are hampering the atrial
fibrillation market growth.
The report has provided a detailed profile of some of the leading players in the global atrial fibrillation
market such as Abbott Laboratories, Biosense Webster, Inc., Medtronic Plc, MicroPort Scientific
Corporation, Boston Scientific Corporation, Biotronik SE & Co. KG, CardioFocus, Inc., AtriCure Inc.,
Koninklijke Philips N.V., and Osypka AG.
Request a PDF Sample -
Global Atrial Fibrillation Market to Witness Robust Growth during the Forecast Period 2017-2026
According to a study by Transparency Market Research (TMR), the global atrial fibrillation market is
expected to witness strong growth. The market is estimated to register 11.0% CAGR during the forecast
period 2017-2026. The market is also estimated to reach US$ 10,925.1 million revenue by the end of
On the basis of product type, the EP ablation catheters are expected to emerge as the most preferred
product in the global atrial fibrillation market. On the basis of end-user, the market is segmented